Niko Klink

PhD candidate @Gerschlab at the CGC of the @MPImoph and @TU_Dortmund. Fascinated by drug discovery and all things Ubiquitin.

[MPI Dortmund @mpimoph]

New Parkinson’s disease paper:
Chimeric deubiquitinase engineering reveals structural basis for specific inhibition of USP30 and a framework for DUB ligandability - published by @MalteGersch group @maxplanckpress in @Nature Struct. & Mol. Biol.
https://t.co/VoRJybRUUI

[Niko Klink @NikolasKlink]

Excited to share that our work on Parkinson's target USP30 has been published in Nature Structural & Molecular Biology! By combining DUB-domains onto USP30, we for the first time achieved crystallization with a small molecule (NK036) without Nanobodies! https://t.co/Pt2hy4WbqT

[Drug Discovery Hub Dortmund @DDHDortmund]

Fighting drug-resistant GIST!🚀 We developed innovative covalent KIT/PDGFRA inhibitors using structure-based design. Check out our latest J Med Chem publication! https://t.co/hOkiSnKkRK

#CancerResearch #DrugDiscovery

[Superti-Furga Lab @gsf_lab]

Kicking off the new year properly: In collaboration between the labs of @giuliosf and @alessiociulli we found that the efflux pump ABCC1/MRP1 constitutively restricts PROTAC sensitivity in cancer cells. Out in @CellChemBiol https://t.co/PbojgA4O6l

[Niko Klink @NikolasKlink]

@TU_Dortmund Besser isses

[MPI Dortmund @mpimoph]

Read how deubiquitinases USP53 and USP54 cleave long polyubiquitin chains and how the former is linked to liver disease in children.
https://t.co/CJMt5KtWZI

[Niko Klink @NikolasKlink]

@alessiociulli @J_A_C_S I remember telling you in a pub in Barcelona that im a big fan of this story :D Great to see this finally out, congrats to the whole Team!

[Malte Gersch @MalteGersch]

Very excited to share that our manuscript on the "Discovery and mechanism of K63-linkage-directed deubiquitinase activity in USP53" was published today at Nature Chemical Biology @nchembio. Congratulations Kim, Kai, and all authors! https://t.co/YTV5td5koG

[CRC 1430 @crc1430]

Tomorrow, November 26, we are looking forward to hosting @georg_e_winter from @CeMM_News, Austrian Academy of Sciences, Vienna, at @crc1430 @unidue. Join us for his exciting talk on small-molecule degraders!

[Niko Klink @NikolasKlink]

@_WolfLab @_MarkusVogt Congrats Markus! Great research, great guy!

[nature @Nature]

“We’re very excited to see what people do with this”

AlphaFold3 is open at last https://t.co/cdvACli8r5

[Niko Klink @NikolasKlink]

I had such a great time at this years AEK autumn school on #degraders and bringing them towards clinical applications. Fantastic Talks from both academia and Industry. I learned alot, got to see old friends and made New ones. Im bringing home great memories and a bunch of notes!

[Niko Klink @NikolasKlink]

@SLorenzLab @MalteGersch @mpimoph It was so nice Meeting you!

[Niko Klink @NikolasKlink]

@georg_e_winter Whos winning?

[ShorterLab @ShorterLab]

Caspase-2 is a condensate-mediated deubiquitinase in protein quality control: https://t.co/hfO79cD8C5

[Niko Klink @NikolasKlink]

@HartungIngo When one candidate does everything to hinder and downtalk science, i personally think the circumstances where a science journal could get involved are met

[Kessler Group Oxford @kesslerlabox]

Looking for E3 / PROTAC / glue or DUB / DUBTAC substrates? Proxy-Ubiquitomics might be the way - applied here to USP30 @AndreasDamiano2 Hannah Jones @ProteomOX
https://t.co/4VV75YCGTK #biorxiv_molbio

[Nature Communications @NatureComms]

In this work, @alessiociulli, @dlzollman, and @UoDCeTPD design and validate a truncated CRBN construct, CRBNmidi, that enables crystallization and biophysical characterization of CRBN-binding ligands and degraders. #TPD #PROTAC

https://t.co/53dSFaeUWV

[Ubiquigent @ubiquigent]

We’re delighted to be partnering with @AlleoLabs to accelerate DUB-focused drug discovery!

This collaboration will combine Alleo’s AI-based platform with our expertise in the DUB space to advance DUB-focused preclinical programmes.
➡ https://t.co/Q853rLK4Cw

[Niko Klink @NikolasKlink]

@Glaconde34 @AstraZeneca I see, thanks!